Skip to content

Climb Bio, Inc. CLYM Free cash flow

Discontinued — last reported Q4 '25

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
Amgen logo
AmgenAMGN
$1.48B+50.7%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$106.52M-95.1%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
-$33.53M+10.8%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
-$33.65M
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$13.49M-12.1%

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Calculated from Climb Bio, Inc.’s reported figures.

The official record: Climb Bio, Inc.’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s free cash flow?
Climb Bio, Inc. (CLYM) reported free cash flow of -$15.64M in Q4 2025.
How has Climb Bio, Inc.'s free cash flow changed year-over-year?
Climb Bio, Inc.'s free cash flow decreased by 183.2% year-over-year, from -$5.52M to -$15.64M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.